TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  The Motley Fool

Should You Buy DexCom Stock Before Oct. 31?

The Motley Fool Logo The Motley Fool By Prosper Junior Bakiny
Should You Buy DexCom Stock Before Oct. 31?

DexCom, a continuous glucose monitoring (CGM) device maker, faces challenges including patient complaints about device accuracy and an FDA warning, but maintains strong revenue growth and significant market potential in diabetes technology.

Insights
MSpI   neutral

Mentioned as one of the analysts raising price target for Bloom Energy


DXCM   neutral

Despite facing legal and regulatory challenges, the company shows strong financial performance, market leadership, and significant growth potential in the CGM market